natgillin/translations-raw huggingface dataset:
Potential complications can often be avoided by ensuring that patients: are not sensitive to human normal immunoglobulin by initially injecting the product slowly (0.5 ml/kg BW/hr); are carefully monitored for any symptoms throughout the infusion period.
Možnim zapletom se lahko pogosto izognete tako, da zagotovite: da bolniki niso preobčutljivi za humani polispecifični imunoglobulin, in sicer tako, da zdravilo najprej injicirate počasi (0,5 ml/kg TM/uro); skrbno spremljanje bolnikov ves čas trajanja infuzije, da bi ugotovili morebitne simptome.
Potential drug interaction risks were not identified from in vitro CYP-inhibition and induction studies, a p-glycoprotein study, or studies of the protein binding of dimethyl fumarate and monomethyl fumarate (a primary metabolite of dimethyl fumarate).
Možnih tveganj medsebojnega delovanja zdravil v študijah in vitro zaviranja in indukcije CYP, študiji p- glikoproteina ali študijah vezave beljakovin dimetilfumarata in monometilfumarata (primarnega presnovka dimetilfumarata) niso opredelili.
Potential drug interactions with drugs that inhibit OCT1 cannot be excluded.
Možnosti medsebojnega delovanja z drugimi zdravili, ki zavirajo OCT1, ni mogoče izključiti.
Potential for Epclusa to affect other medicinal products
Možnost vpliva zdravila Epclusa na druga zdravila
Potential for Exviera to affect the pharmacokinetics of other medicinal products
Možnost vpliva zdravila Exviera na farmakokinetiko drugih zdravil
Potential for Harvoni to affect other medicinal products
Možnost vpliva zdravila Harvoni na druga zdravila
Potential for hypersensitivity or anaphylactic reactions
Možnost preobčutljivostne ali anafilaktične reakcije
Potential for hypersensitivity or anaphylactic reactions
Možnost preobčutljivostnih ali anafilaktičnih reakcij
Potential for hypersensitivity or anaphylactic reactions
Potencial za preobčutljivost ali anafilaktične reakcije
potential for increased adverse
lahko zveča možnost za neželene
Potential for interaction following intramuscular injection
Možnost za medsebojno delovanje po intramuskularnem injiciranju
Potential for interaction with other medicinal products
Možne interakcije z drugimi zdravili
Potential for interference with opioid-mediated analgesia
Možnost oviranja analgezije z opioidi
Potential for INVEGA to affect other medicines
Možnost, da bo zdravilo INVEGA vplivalo na druga zdravila
Potential for lumacaftor/ivacaftor to affect other medicinal products
Možnost, da bo lumakaftor/ivakaftor vplival na druga zdravila
Potential for lumacaftor/ivacaftor to interact with transporters
Potencial lumakaftorja/ivakaftorja za medesebojno delovanje s prenašalci
Potential for Off-label Use
Možnost uporabe zunaj okvira odobrenih indikacij ("off-label use")
Potential for olanzapine to affect other medicinal products
Vpliv olanzapina na druga zdravila
Potential for olanzapine to affect other medicinal products
Zmožnost vpliva olanzapina na druga zdravila
Potential for olanzapine to affect other medicinal products:
Zmožnost vplivanja olanzapina na druga zdravila
Potential for other medicinal products to affect ABILIFY solution for injection
Možnost vpliva drugih zdravil na aripiprazola
Potential for other medicinal products to affect abiraterone exposures
Možnost vpliva drugih zdravil na izpostavljenost abirateronu
Potential for other medicinal products to affect Epclusa
Možnost vpliva drugih zdravil na zdravilo Epclusa
Potential for other medicinal products to affect Harvoni
Možnost vpliva drugih zdravil na zdravilo Harvoni
Potential for other medicinal products to affect lumacaftor/ivacaftor
Možnost, da bodo druga zdravila vplivala na lumakaftor/ivakaftor
Potential for other medicinal products to affect lurasidone
Možen vpliv drugih zdravil na delovanje lurasidona
Potential for other medicinal products to affect tasimelteon
Možnost vpliva drugih zdravil na tasimelteon
Potential for other medicinal products to affect the pharmacokinetics of dasabuvir
Možnost vpliva drugih zdravil na farmakokinetiko dasabuvirja
Potential for other medicinal products to affect the pharmacokinetics of ombitasvir, paritaprevir, and dasabuvir
Možnost vpliva drugih zdravil na farmakokinetiko ombitasvirja, paritaprevirja in dasabuvirja
Potential for other medicinal products to affect ulipristal acetate
Možnost vpliva drugih zdravil na ulipristalacetat
Potential for other medicines to affect INVEGA
Možnost, da bodo druga zdravila vplivala na zdravilo INVEGA
Potential for other medicines to affect Sycrest
Možnost, da bi druga zdravila vplivala na zdravilo Sycrest
Potential for pharmacodynamic interactions with avanafil
Potencial za farmakodinamične interakcije z avanafilom
Potential for retinal degeneration in patients with presence/prior history of retinal disease
Potencial za degeneracijo mrežnice pri bolnikih z boleznijo mrežnice/boleznijo mrežnice v anamnezi
Potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by
Možnost za resne in/ali življenjsko ogrožujoče reakcije, kot npr. akutna ergot toksičnost, ki se kaže kot periferni vazospazem in ishemija ekstremitet in ostalih tkiv.
Potential for serious and/or life-threatening reactions such as cardiac arrhythmias.
Možnost za resne in/ali življenjsko ogrožujoče reakcije kot npr. srčne aritmije.
Potential for Sycrest to affect other medicines
Možnost, da bi zdravilo Sycrest vplivalo na druga zdravila
Potential for tumour cell mobilisation in patients with lymphoma and multiple myeloma The effect of potential re-infusion of tumour cells has not been adequately studied.
Možnost mobilizacije tumorskih celic pri bolnikih z limfomom ali multiplim mielomom Učinka potencialne ponovne infuzije tumorskih celic še niso ustrezno raziskali.
Potential for Viekirax to affect the pharmacokinetics of other medicinal products
Možni vplivi zdravila Viekirax na farmakokinetiko drugih zdravil
Potential for zonisamide to affect other medicinal products
Možni učinki zonisamida na druga zdravila
potential inhibition of CYP3A by
možnega zaviranja CYP3A z
Potential interactions affecting agomelatine
Možna medsebojna delovanja, ki vplivajo na agomelatin
Potential interactions affecting olanzapine:
Možna medsebojna delovanja, ki vplivajo na olanzapin
Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug- drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate).
Potencialne interakcije brivaracetama (od 50 mg/dan do 200 mg/dan) z drugimi antiepileptiki so preiskovali v združeni analizi plazemskih koncentracij zdravil iz vseh študij faze 2–3 v populacijski farmakokinetični analizi s placebom nadzorovanih študij faze 2–3 in v namenskih študijah interakcij med dvema zdraviloma (za naslednje antiepileptike: karbamazepin, lamotrigin, fentoin in topiramat).
Potential interactions between brivaracetam (50 mg/day to 200 mg/day) and other AEDs were investigated in a pooled analysis of plasma drug concentrations from all phase 2-3 studies, in a population pharmacokinetic analysis of placebo-controlled phase 2-3 studies, and in dedicated drug- drug interaction studies (for the following AEDs: carbamazepine, lamotrigine, phenytoin and topiramate).
Potencialne interakcije brivaracetama (od 50 mg/dan do 200 mg/dan) z drugimi antiepileptiki so preiskovali v združeni analizi plazemskih koncentracij zdravil iz vseh študij faze 2–3 v populacijski farmakokinetični analizi s placebom nadzorovanih študij faze 2–3 in v namenskih študijah interakcij med dvema zdraviloma (za naslednje antiepileptike: karbamazepin, lamotrigin, fentoin in topiramat).
Potential interactions between Fycompa (up to 12 mg once daily) and other anti-epileptic drugs (AEDs) were assessed in clinical studies and evaluated in the population PK analysis of four pooled Phase 3 studies including patients with partial onset seizures and primary generalised tonic-clonic seizures.
Možne interakcije med zdravilom Fycompa (do 12 mg enkrat na dan) in drugimi antiepileptičnimi zdravili (AEZ) so ocenili v kliničnih študijah in ovrednotili v farmakokinetični analizi populacije štirih združenih študij 3. faze, ki so zajemale tudi bolnike z napadi parcialnega izvora in primarnimi generaliziranimi napadi s tonično-kloničnimi krči.
Potential interactions may occur with active substances which are metabolised by, or are inhibitors or inducers of, these enzymes.
Z zdravilnimi učinkovinami, ki se presnavljajo s temi encimi, jih zavirajo ali pa so njihovi induktorji, lahko pride do interakcij.
Potential Interactions with antithrombotic fibrinolytic agents
Morebitne interakcije z antitrombotičnimi fibrinolitičnimi učinkovinami
Potential Interactions with other medicinal products
Morebitne interakcije z drugimi zdravili
Potential Interactions with recombinant t-PA
Morebitne interakcije z rekombinantnim t-PA
Potential medicinal product interactions affecting zonisamide
Možni medsebojni učinki zdravil na zonisamid
Potential risk of teratogenicity
potencialno tveganje teratogenosti
Potential risks associated with acetylsalicylic acid therapy should be considered prior to co-administration with Tecfidera. (see sections 4.2, 4.4 and 4.8).
Pred sočasnim dajanjem z zdravilom Tecfidera je treba upoštevati možna tveganja, povezana s terapijo z acetilsalicilno kislino (glejte poglavja 4.2, 4.4 in 4.8).
potential serious and/or life
resnih ali življenjsko nevarnih
Potential side effects
Možni neželeni učinki
Potential systemic effects may include Cushing’s syndrome, Cushingoid features, adrenal suppression, growth retardation in children and adolescents, cataract, glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children).
Med možnimi sistemskimi učinki so lahko Cushingov sindrom, Cushingoidne značilnosti, zavora delovanja nadledvičnih žlez, upočasnitev rasti pri otrocih in mladostnikih, katarakta, glavkom in, redkeje, vrsta psiholoških ali vedenjskih učinkov, med njimi psihomotorična hiperaktivnost, motnje spanja, anksioznost, depresija ali napadalnost (zlasti pri otrocih).
Potential to affect exposures to other medicinal products
Možnost vpliva abiraterona na izpostavljenost drugim zdravilom
Potential to exacerbate immunosuppression: Pancytopenia and bone marrow suppression have been reported in the literature to occur within 3 to 7 weeks after the administration of a peginterferon and ribavirin concomitantly with azathioprine.
V literaturi so poročali o pancitopeniji in supresiji kostnega mozga, ki sta se pojavili v 3 do 7 tednih po dajanju peginterferona in ribavirina sočasno z azatioprinom.
Potential to slightly decrease abacavir plasma concentrations through UGT induction.
Obstaja možnost za rahlo znižanje plazemske koncetracije zidovudina preko indukcije UGT.
Potential to slightly decrease zidovudine plasma concentrations through UGT induction.
Obstaja možnost za rahlo znižanje plazemske koncetracije abakavirja preko indukcije UGT.
Potential undesirable effects
Možni neželeni učinki
Potential ↑ in plasma concentrations of methadone
Morebitno ↑ koncentracij metadona v plazmi
Potential ↑in plasma concentrations of carbamazepine and phenytoin
Morebitno ↑ koncentracij karbamazepina in fenitoina v plazmi
Potential ↑in plasma concentrations of vinca alkaloids.
Morebitno ↑ koncentracij alkaloidov rožnatega zimzelena v plazmi.
Potential ↓ in plasma concentrations of ketoconazole are expected.
Pričakovano je morebitno ↓ koncentracij ketokonazola v plazmi.
Potentially contributing factors were present in several of these patients that may have independently increased their risk of seizure.
Več teh bolnikov je imelo potencialne dodatne dejavnike, ki so lahko neodvisno povečali tveganje za konvulzije.
Potentially high (up to 700 µM) eluxadoline concentrations in gut may affect the pharmacokinetic of concomitantly administered CYP3A4 substrates (see section 4.5).
Visoke (do 700 µM) koncentracije eluksadolina v črevesu bi lahko vplivale na farmakokinetiko sočasno uporabljenih substratov CYP3A4 (glejte poglavje 4.5).
Potentially immunocomplex-mediated reactions
Morebitne reakcije, povzročene z imunskimi kompleksi
Potentially immunocomplex-mediated reactions
Reakcije povzročene z imunokompleksi
Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Občasno so poročali o reakcijah povzročenih z imunokompleksi, kot so serumska bolezen, poliartritis z izpuščajem in proliferativni glomerulonefritis.
Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Občasno so poročali o reakcijah, morda povzročenih z imunskimi kompleksi, kot so serumska bolezen, poliartritis z izpuščajem in proliferativni glomerulonefritis.
Potentially immunocomplex-mediated reactions, such as serum-sickness-type reaction, polyarthritis with rash and proliferative glomerulonephritis have been reported uncommonly.
Občasno so poročali o reakcijah, povzročenih z imunskimi kompleksi, kot so serumska bolezen, poliartritis z izpuščajem in proliferativni glomerulonefritis.
Potentially infected biological material.
Potencialno kužni biološki material.
potentially life threatening cardiac
(sakvinavir/ritonavir)
Potentially life-threatening complication of whole body inflammation (septic shock)
potencialno življenjsko nevarni zapleti z vnetjem celega telesa (septični šok),
Potentially life-threatening skin rashes (Stevens-Johnson syndrome and Erythema Multiforme) have been reported with the use of CHAMPIX.
Pri uporabi zdravila CHAMPIX so poročali o potencialno smrtno nevarnih kožnih izpuščajih (Stevens-Johnsonov sindrom in multiformni eritem).
Potentially life-threatening, irregular heart beat (torsade de pointes);
potencialno smrtno nevaren nereden srčni ritem (torsade de pointes);
Potentiated systemic beta-blockade (e.g. decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.
Pri sočasnem zdravljenju z zaviralci CYP2D6 (npr. kinidinom, fluoksetinom in paroksetinom) in timololom so poročali o potenciranem sistemskem učinku antagonistov adrenergičnih receptorjev beta (npr. zmanjšanem srčnem utripu, depresiji).
Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported during combined treatment with CYP2D6 inhibitors (e.g. quinidine, fluoxetine, paroxetine) and timolol.
Pri sočasnem zdravljenju z zaviralci izoencima CYP2D6 (npr. kinidinom, fluoksetinom, paroksetinom) in timolola so poročali o okrepljeni sistemski beta blokadi (npr. zmanjšani srčni frekvenci, depresiji).
Potentiation of orthostatic hypotension may occur;
Pojavi se lahko ortostatska hipotenzija.
Potentiation of radiation toxicity: Radiation recall and radiation sensitization have been observed from post-marketing sources.
Povečanje toksičnosti obsevanja: Po prihodu zdravila na trg so opazili vnetne reakcije na mestu obsevanja (t.i. radiation recall) in povečano občutljivosti na obsevanje.
Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur when one of the following active substances is taken, for example:
Ob jemanju katere izmed naslednjih učinkovin se lahko poveča učinek na znižanje koncentracije glukoze v krvi, zato lahko v nekaterih primerih pride do hipoglikemije:
Potters Bar Hertfordshire EN6 1TL
Potters Bar Hertfordshire EN6 1 TL
Potters Bar Hertfordshire EN6 1TL United Kingdom
Potters Bar Hertfordshire EN6 1 TL Velika Britanija
Potters Bar Hertfordshire EN6 1TL United Kingdom
Potters Bar Hertfordshire EN6 1TL Velika Britanija
Potters Bar, Hertfordshire, EN6 1TL, UK
NAČIN IZDAJANJA ZDRAVILA
Potters Bar, Hertfordshire, EN6 1TL, UK
Potters Bar, Hertfordshire, EN6 1TL, Združeno kraljestvo
POUCH
VREČKA
pouch (foil)
mošnjiček (folija)
POUCH containing pre-filled syringe, a plunger stopper and a pre-attached plunger rod
Vrečka, ki vsebuje napolnjeno injekcijsko brizgo z že vstavljenim potisnim batom in gumijastim tesnilom
POUCH LABEL
NALEPKA NA VREČICI
Poulvac E. coli lyophilisate for suspension for spray vaccination for chickens and turkeys or for use in drinking water for chickens
Poulvac E. coli Liofilizat za suspenzijo za cepljenje s pršenjem za piščance in purane ali za dajanje v vodo za pitje za piščance.
Poulvac E. coli, like all vaccines, works by ‘teaching’ the immune system (the body’s natural defences) how to defend itself against a disease.
Cepivo Poulvac E. coli deluje kot vsa cepiva tako, da imunski sistem (naravni obrambni mehanizem telesa) „nauči“, kako naj se brani pred boleznijo.
Poulvac FluFend H5N3 RG Emulsion for injection for chickens and ducks
Poulvac FluFend H5N3 RG emulzija za injiciranje za piščance in race
Pounding heartbeat
razbijanje srca;
pounding or irregular heart beat
razbijanje srca ali nepravilna frekvenca srčnega utripa
pounding or irregular heartbeat
razbijanje srca ali nereden srčni utrip
pounding or irregular heartbeat,
razbijanje srca ali nereden srčni utrip,
Pour a volume of water equal to the calculated volume of product needed into the measuring device.
Vlijte količino vode, ki je enaka izračunanemu volumnu zdravila, v merilno napravo.
Pour a volume of water equal to the calculated volume of product needed into the measuring device.
Vlijto količino vode, ki je enaka izračunanemu volumnu zdravila, v merilno napravo.
Pour all of the powder into the bowl.
Stresite ves prašek v posodo.
Pour all of the powder into the mixing cup.
Vsujte ves prašek v posodico za mešanje.
Pour all of the prepared Cayston from the vial into the Altera Nebuliser Handset medicine reservoir (Figure 2a).
Celotno količino pripravljenega zdravila Cayston vlijte iz viale v vsebnik za zdravilo kompleta z nebulatorjem Altera (slika 2a).
Pour all of the water from the jug into the bottle, onto the powder.
Vso vodo iz čaše prelijte v steklenico, na prašek.
Pour any leftover medicine from the mixing cup into a rubbish bag.
Preostalo količino zdravila v posodici za mešanje izpraznite v vrečo za smeti.
Pour away the remaining water from the mixing cup.
Preostalo vodo izlijte iz posodice za mešanje.
Pour entire contents of the sachet into 5 ml of water and mix
Vsebino celotne vrečice stresite v 5 ml vode in zmešajte.
Pour entire contents of the sachet into the 4.6 mL of water and mix.
Celotno vsebino vrečke stresite v 4,6 ml vode in zmešajte.
Pour granules directly into the spoon as shown by the picture (on the outer carton and at the end of/page 2 of this leaflet)
zrnca stresite neposredno na žličko, kot kaže slika (na zunanji ovojnini in na koncu strani 2 tega navodila);
Pour the amount of water into the medicine cup, as instructed by your doctor (e.g. your doctor told you to use 20 ml for dissolving one Kuvan tablet).
V lonček za zdravilo vlijte količino vode, kot vam je naročil zdravnik (npr. zdravnik vam je povedal, da za raztopitev ene tablete zdravila Kuvan uporabite 20 ml vode).
Pour the contents into a drinking glass.
Prelijte vsebino v kozarec.
Pour the entire contents of 1 sachet (100 mg) into the mixing cup.
Vsujte celotno vsebino 1 vrečice (100 mg) v posodico za mešanje.
Pour the MAM and SSCS into separate developing tanks to a depth of approximately 0.5 cm.
Natočite MAM in SSCD v dva ločena generatorja za razvijanje do globine približno 0,5 cm.
Pour the powder into half a glass of water (120 ml)
Vsujte prašek v pol kozarca vode (120 ml).
Pour the powder into half a glass of water.
Prašek vsujte v pol kozarca vode.
Pour the powder into the cup
Vsujte prašek v posodico
Povidone
povidon,
Povidone
Želatina Povidon
Povidone (E1201) Microcrystalline cellulose (E460i) Colloidal anhydrous silica Sodium benzoate (E211)
povidon (E1201) mikrokristalna celuloza (E460i) brezvodni koloidni silicijev dioksid natrijev benzoat (E211)
Povidone (E1201), Microcrystalline cellulose (E460i), Colloidal anhydrous silica, Sodium benzoate (E211).
Povidon (E1201), mikrokristalna celuloza (E460i), brezvodni koloidni silicijev dioksid, natrijev benzoat (E211).
Povidone Croscarmellose sodium Sodium stearyl fumarate
povidon natrijev premrežen karmelozat natrijev stearilfumarat
Povidone Film-coating
Filmska obloga
Povidone K 29/32 Croscarmellose sodium Magnesium stearate
povidon K 29/32 premreženi natrijev karmelozat magnezijev stearat
Powder
Prašek:
Powder
Stungulyfsstofn
Powder (1000 IU) in a 6 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (1000 i.e) v 6 ml viali (steklo tipa I), z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
Powder (1000 IU/2400 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (1000 i.e./2400 i.e.) v viali (steklo tipa I) z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
Powder (2000 IU) in a 10 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (2000 i.e) v 10 ml viali (steklo tipa I), z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
Powder (250 IU) in a 6 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (250 i.e) v 6 ml viali (steklo tipa I), z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
Powder (250 IU/600 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (250 i.e./600 i.e.) v viali (steklo tipa I) z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
Powder (500 IU) in a 6 ml vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (500 i.e) v 6 ml viali (steklo tipa I), z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
Powder (500 IU/1200 IU) in a vial (type I glass), with a stopper (rubber) a disc (plastic) and a cap (aluminium).
Prašek (500 i.e./1200 i.e.) v viali (steklo tipa I) z zamaškom (gumijast), okroglo ploščico (plastična) in zaporko (aluminijasta).
powder (carmellose): vial (glass/alu)
viala (steklo/aluminij); Prašek (karmeloza): viala (steklo/aluminij)
Powder 250 µg (500 µg/ml)
Prašek: 250 µg (500 µg/ml)
Powder 3000 IU;
prašek : 3000 IU;
Powder also contains: alanine, mannitol, disodium phosphate dodecahydrate, disodium phosphate dihydrate, sodium dihydrogen phosphate dihydrate
Prašek vsebuje tudi: alanin, manitol, natrijev hidrogenfosfat dodekahidrat, natrijev hidrogenfosfat dihidrat, natrijev dihidrogenfosfat dihidrat.
Powder and
prašek in
Powder and
prašek in topilo:
Powder and diluent: 3 years.
Prašek in vehikel: 3 leta.
Powder and gel for gel
prašek in gel za gel
Powder and gel for gel.
Prašek in gel za gel.
Powder and gel must be mixed thoroughly until a uniform, slightly tan to slightly brown mixture is obtained.
Prašek in gel morate dobro premešati, da dobite enakomerno, rahlo svetlorjavo do rjavkasto mešanico.
Powder and solvent
Prašek in vehikel
Powder and solvent
prašek in vehikel za
Powder and solvent
Prašek in vehikel za suspenzijo za injiciranje.
Powder and solvent for
Prašek in
Powder and solvent for
prašek in vehikel za
Powder and solvent for
Prašek in vehikel za raztopino za injiciranje
powder and solvent for concentrate for solution for infusion
prašek in vehikel za pripravo koncentrata za raztopino za infundiranje
Powder and solvent for concentrate for solution for infusion 1 vial and 1 ampoule
Prašek in vehikel za koncentrat za raztopino za infundiranje 1 viala in 1 ampula
Powder and solvent for concentrate for solution for infusion 3 vials and 3 ampoules
Prašek in vehikel za koncentrat za raztopino za infundiranje 3 viale in 3 ampule
Powder and solvent for concentrate for solution for infusion.
Docefrez, 20 mg/0.5 ml, prašek in vehikel za pripravo koncentrata za raztopino za infundiranje
Powder and solvent for concentrate for solution for infusion.
Prašek in vehikel za pripravo koncentrata za raztopino za infundiranje.